Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
View original at globenewswire.comZentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedb…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Azenosertib is a potentially first-in-class and best-in-class WEE1 inhibitor
80% confidenceCompany expects to disclose topline data from DENALI Part 2 by year end 2026
80% confidenceFurther development in USC will be limited to partnering or the Company's ability to allocate capital to this indication
80% confidenceResults from the TETON trial are planned for publication in the first half of 2026
80% confidenceDENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review
80% confidenceDENALI clinical trial remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback
80% confidenceIn clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types
80% confidence$280.7 million in cash provides runway into late 2027
80% confidenceExisting cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to fund operating expenses requirements into late 2027
80% confidence